At a glance
ClinicalIndex Comparison RecordN/ACompleted· 244 enrolled
Drug / intervention
MiniMed 780G Systemdevice
Likely dose
MiniMed 780G Systemfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
In Brief
A clinical study evaluating MiniMed 780G System for Type 1 Diabetes. Completed, enrolled 244 participants across 19 sites.
Detailed Summary
This US study will evaluate the safety and effectiveness of utilizing insulin Lyumjev® lispro-aabc in the MiniMed™ 780G System in Type 1 adult and pediatric subjects in a home setting to support product and system labeling.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionJan 2024
TodayJul 2026
First PostedApr 13, 2022
Enrollment StartMay 5, 2022
Primary CompletionJan 3, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.2 years ago
Interventions
MiniMed 780G Systemdevice
MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc